These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9097988)

  • 1. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
    Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
    Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
    Mahmud N; Kamm MA; Dupas JL; Jewell DP; O'Morain CA; Weir DG; Kelleher D
    Gut; 2001 Oct; 49(4):552-6. PubMed ID: 11559654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
    J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
    McLeod RS; Wolff BG; Steinhart AH; Carryer PW; O'Rourke K; Andrews DF; Blair JE; Cangemi JR; Cohen Z; Cullen JB
    Gastroenterology; 1995 Aug; 109(2):404-13. PubMed ID: 7615189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
    Singleton JW; Hanauer S; Robinson M
    Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
    Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB
    Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
    N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.